Synthetic cannabinoid use among patients in residential substance use disorder treatment: Prevalence, motives, and correlates
Synthetic cannabinoid use among patients in residential substance use disorder treatment: Prevalence, motives, and correlates
复制标题
DOI：
10.1016/j.drugalcdep.2014.07.009
复制
发表时间：
2014-10-01
影响因子：
4.2
通讯作者：
Ilgen, Mark A.
中科院分区：
文献类型：
--
作者：
Bonar, Erin E.;Ashrafioun, Lisham;Ilgen, Mark A.
背景：过去几年，合成大麻素的滥用已成为一个公共卫生问题，但很少有数据描述合成大麻素的使用，特别是在寻求物质使用障碍（SUD）治疗的患者中。在进入住院 SUD 治疗的患者样本中，我们检查了合成大麻素使用的流行率和动机，并检查了合成大麻素使用与其他物质使用和人口特征的关系。 方法：患者（N = 396；67% 男性，75% 白人，Mage = 34.8）完成了有关合成大麻素使用终生流行率、给药途径和使用动机的自我报告筛查调查。 结果：总共150 名患者 (38%) 报告称在其一生中使用过合成大麻素，主要通过吸烟 (91%)。参与者选择了多种使用动机，最常见的动机包括好奇（91%）、感觉良好/兴奋（89%）、放松（71%）以及在药检呈阳性的情况下兴奋（71%）。从人口结构来看，使用合成大麻素的人更年轻，而且更多是白人。他们使用其他物质的比例较高，在抑郁和精神困扰方面的得分也较高。结论：在 SUD 患者中，终生使用合成大麻素相对常见，许多使用它的人报告这样做是因为他们认为这不会导致药物测试呈阳性。需要进一步研究来表征 SUD 治疗样本中合成大麻素使用的程度，并了解合成大麻素使用与其他物质使用、精神困扰和治疗结果相结合的纵向轨迹。 (C) 2014 Elsevier Ireland Ltd. 保留所有权利。
Background: The abuse of synthetic cannabinoids has emerged as a public health concern over the past few years, yet little data exist characterizing the use of synthetic cannabinoids, particularly among patients seeking substance use disorder (SUD) treatment. In a sample of patients entering residential SUD treatment, we examined the prevalence of and motivations for synthetic cannabinoid use, and examined relationships of synthetic cannabinoid use with other substance use and demographic characteristics.Methods: Patients (N = 396; 67% male, 75% White, Mage = 34.8) completed self-report screening surveys about lifetime prevalence of synthetic cannabinoid use, route of administration, and motives for use.Results:A total of 150 patients (38%) reported using synthetic cannabinoids in their lifetimes, primarily by smoking (91%). Participants chose multiple motives for use and the most commonly endorsed included curiosity (91%), feeling good/getting high (89%), relaxation (71%), and getting high without having a positive drug test (71%). Demographically, those who used synthetic cannabinoids were younger and more were White. They had higher rates of other substance use and higher scores on measures of depression and psychiatric distress.Conclusions: Lifetime synthetic cannabinoid use was relatively common in SUD patients and many of those who used it reported doing so because they believed it would not result in a positive drug test. Further research is needed to characterize the extent of synthetic cannabinoid use among SUD treatment samples, and to establish understanding of the longitudinal trajectories of synthetic cannabinoid use in combination with other substance use, psychiatric distress, and treatment outcomes. (C) 2014 Elsevier Ireland Ltd. All rights reserved.